drugset / Trial / NCT01440478

The Effects of Urinary pH Changes on an Investigational Compound in Healthy Subjects

NCT01440478

Phase 1 Completed 30 enrolled Eli Lilly and Company
RandomizedCrossoverOpen-labelBasic science

Summary

This study is designed to explore the effect of increased and decreased urinary pH on the single pharmacokinetic (PK) dose of LY2140023 and its active metabolite LY404039. All participants will receive the three treatments in a randomized order.

Timeline

Start
2011-09
Primary completion
2011-10
Completion
2011-10

Drugs

EvaluationDrugModalityDoseRoute
Subject LY2140023 Unknown 80 mg Oral
Background Ammonium Chloride Small molecule 1 g Oral
Background sodium bicarbonate Diagnostic / imaging agent 4 g Oral

Indications

No indication recorded.